Core Insights - DarioHealth Corp. achieved its strongest year on record in 2025, signing 85 new agreements, significantly exceeding its target of four, with average contract sizes two to ten times larger than historical averages [6][24] - The company experienced a decline in annual revenue due to a single legacy client not renewing its contract, but the underlying business showed strong growth potential with new agreements contributing to future revenue [6][30] - DarioHealth's commercial pipeline has expanded to $122 million, indicating strong revenue visibility and a foundation for sustained growth [8][24] Financial Performance - Revenue for the twelve months ended December 31, 2025, was $22.4 million, down from $27.0 million in 2024, primarily due to the non-renewal of a legacy client [30] - GAAP gross margin improved from 49% in 2024 to 57% in 2025, reflecting reduced technology amortization expenses [30] - Total operating expenses declined by 31% to $49.3 million in 2025 compared to 2024, with non-GAAP operating expenses down by 26% year-over-year [30] Growth Strategy - The company is focusing on a two-layer growth strategy: client scale through channel partnerships and member scale via its multi-condition platform [28] - DarioHealth is transitioning towards large payer ecosystems and curated digital health networks, allowing for broader distribution of its integrated platform [18][19] - The demand for integrated digital health solutions is increasing as employers seek measurable outcomes and simplified vendor ecosystems [24][16] Market Positioning - DarioHealth's fully vertically integrated platform is designed to address multiple chronic conditions, making it a preferred partner for employers and health plans [11][16] - The company is actively engaged in discussions with state offices regarding digital health infrastructure as part of rural health transformation initiatives, indicating potential growth in government-sponsored healthcare programs [23] - The market is shifting towards integrated platforms that deliver measurable clinical and financial outcomes, positioning DarioHealth favorably in the evolving digital health landscape [16][12] Future Outlook - The company expects to narrow its non-GAAP operating loss by approximately 30% in 2026 and aims for cash flow breakeven by mid-2027 [32] - DarioHealth anticipates revenue growth to continue in 2026, with the second half of the year expected to show the strongest acceleration [8][7] - The company is exploring emerging opportunities within the pharmaceutical services segment, indicating potential for future revenue growth [27]

Executive Narrative - Henry Schein, Inc. achieved the highest sales growth in 15 quarters, driven by the effective execution of the BOLD+1 strategic plan and recovery from previous cybersecurity disruptions [4] - High-growth, high-margin businesses now account for nearly 50% of total operating income, indicating a strategic shift towards specialty products and technology solutions [4] - Global dental equipment sales reached record levels, with double-digit growth in traditional equipment and market share gains from technical service capabilities [4] Sales and Market Performance - U.S. dental merchandise growth was supported by data-driven marketing initiatives and increased procedure volumes, as indicated by Henry Schein One eClaims activity [4] - The Global Technology segment saw a 20% year-over-year increase in cloud-based subscribers, exceeding 11,000 Dentrix Ascend users globally [4] Strategic Initiatives - Strategic partnerships with Amazon Web Services are integrating generative and agentic AI into practice management systems to automate administrative workflows and clinical documentation [4] - Management attributes recent success to a shift from internal recovery efforts back to aggressive market engagement and sales force expansion [4] Future Projections - Sales growth for 2026 is projected at 3% to 5%, assuming stable dental and medical end markets and consistent foreign currency exchange rates [4] - Earnings growth is expected to be more heavily weighted towards the second half of 2026 as value creation initiatives reach full implementation [4] - Value creation projects are targeted to deliver over $125 million in annual run-rate operating income improvement by the end of 2026 [4] E-commerce and Restructuring - The rollout of the new henryschein.com e-commerce platform is scheduled for completion for U.S. dental and Canadian customers in Q1 2026 [4] - The company recorded $105 million in total restructuring expenses for the full year 2025 related to the program announced in August 2024 [4] Market Challenges - U.S. medical sales face headwinds from lower comparative demand in respiratory products and vaccinations following post-pandemic normalization [6] - Management indicated that potential tariff impacts can be mitigated through alternative sourcing and passing costs through to customers [6]

Core Insights - Henry Schein reported its highest sales growth in 15 quarters, with fourth-quarter global sales reaching $3.4 billion, up 7.7% year over year, driven by strong performance across various segments [2][4][6]. Financial Performance - The company reported a fourth-quarter GAAP operating margin of 4.76%, down 10 basis points from the prior year, while the non-GAAP operating margin was 7.42%, remaining relatively flat year over year [1]. - Fourth-quarter GAAP net income was $101 million, or $0.85 per diluted share, compared to $94 million, or $0.74 per diluted share, in the prior-year period. Non-GAAP net income was $160 million, or $1.34 per diluted share, up from $149 million, or $1.19 per diluted share [7]. - Adjusted EBITDA for the fourth quarter was $291 million, an increase from $270 million, representing an 8.4% growth [7]. Segment Performance - Global specialty products saw sales growth of 14.6%, driven by strong performance in implants and biomaterials, with double-digit growth in value implants [10]. - Global technology sales grew 8.4%, supported by practice management software and significant growth in Dentrix Ascend, which surpassed 11,000 subscribers [11]. - The global distribution and value-added services group delivered 7.0% sales growth, with U.S. dental merchandise sales growing by 3.6% and U.S. dental equipment sales growing by 10.6% [8][9]. Leadership Transition - Fred Lowery will officially join as CEO next week, with a focus on a 100-day "listening tour" to validate existing initiatives and engage with stakeholders [3][6]. - Stanley Bergman will remain as Chairman of the Board, emphasizing Lowery's experience in scaling businesses through acquisitions and organic growth [4][6]. Strategic Initiatives - The company expects over $200 million of operating income improvement through cost savings and incremental gross margin opportunities, with an annual run-rate improvement of over $125 million by the end of 2026 [13]. - Henry Schein repurchased 2.8 million shares for $200 million at an average price of $71.10 per share, ending the year with approximately $780 million remaining under its authorization [14]. 2026 Outlook - For 2026, Henry Schein guided to sales growth of 3% to 5% and non-GAAP diluted EPS of $5.23 to $5.37, representing 5% to 8% growth compared to 2025 [15]. - The guidance assumes stable dental and medical end markets and consistent foreign exchange rates [15][16].